Back to Search
Start Over
Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus
- Source :
- Expert Opinion on Pharmacotherapy. 12:1457-1461
- Publication Year :
- 2011
- Publisher :
- Informa Healthcare, 2011.
-
Abstract
- Several classes of drugs have been developed to treat type 2 diabetes mellitus (T2DM). Pioglitazone is now the only thiazolidinedione approved for the treatment of T2DM and can be administered in combination with metformin, sulfonylureas, exenatide, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin. It improves glycemic control with an extremely low incidence of hypoglycemia. In addition to reducing insulin resistance, it may also improve pancreatic beta-cell secretory function. Moreover, it exhibits a variety of favorable pleiotropic effects. The latter include anti-inflammatory, antioxidant, vasoprotective, antihypertensive and hypolipidemic actions. Finally, this agent has been shown to improve experimental diabetic neuropathy and alleviate neuropathic pain, as well as decreasing urinary albumin excretion in patients with diabetes. Thus, pioglitazone emerges as a valuable hypoglycemic agent for combination therapy in T2DM. Importantly, however, patients should be appropriately selected, especially to avoid those with heart failure, in order to minimize adverse events attributable to water retention.
- Subjects :
- Blood Glucose
endocrine system diseases
medicine.drug_class
Pharmacology
Hypoglycemia
Insulin resistance
Diabetes mellitus
medicine
Humans
Hypoglycemic Agents
Pharmacology (medical)
Thiazolidinedione
Pioglitazone
business.industry
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
General Medicine
medicine.disease
Metformin
Diabetes Mellitus, Type 2
Drug Therapy, Combination
Thiazolidinediones
Insulin Resistance
business
Exenatide
medicine.drug
Subjects
Details
- ISSN :
- 17447666 and 14656566
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....bace0d7c35503becf97797be7cfebfd1